Veterinary Medicines

Virbagen canis SHAP/L

Authorised
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle VR128, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
Download as PDF

Product identification

Medicine name:
Virbagen canis SHAP/L
Active substance:
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle VR128, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus, strain Cornell 780916, Live
    100000.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan, Live
    10000.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine distemper virus, strain Lederle VR128, Live
    1000.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
    4250.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
    4350.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac Tierarzneimittel GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • VIRBAC
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 107a/90
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 19/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."